LGVN Latest Press Releases

-- October 28, 2026 --

Longeveron Announces Engagement of Lucid Capital Markets Globe Newswire 9:15 AM

-- October 26, 2026 --

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) Globe Newswire 9:15 AM

-- September 30, 2026 --

Longeveron to Participate in Three Longevity/Aging Investment Conferences Globe Newswire 4:05 PM

-- September 16, 2026 --

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) Globe Newswire 5:27 PM

-- September 3, 2026 --

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 9:15 AM

-- August 24, 2026 --

Longeveron Announces 1-for-10 Reverse Stock Split Globe Newswire 4:05 PM

-- August 19, 2026 --

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer Globe Newswire 4:05 PM

-- August 12, 2026 --

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- August 11, 2026 --

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition Globe Newswire 9:05 AM

-- August 3, 2026 --

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026 Globe Newswire 4:05 PM

-- July 23, 2026 --

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors Globe Newswire 9:15 AM

-- July 13, 2026 --

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease Globe Newswire 7:05 AM

-- July 6, 2026 --

Longeveron Appoints Marie Washburn as Chief Financial Officer Globe Newswire 4:05 PM

-- June 18, 2026 --

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) Globe Newswire 9:20 AM

-- June 9, 2026 --

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) Globe Newswire 9:20 AM

-- June 4, 2026 --

Longeveron to Present at BIO International Convention 2026 Globe Newswire 9:15 AM

Market Data Delayed 15 Minutes